Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5959789 | 0.90 | PPARD (0.55) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL5959607 | 0.89 | PPARD (0.49) | PPARDPPARGPPARAFFAR1 | |
| SCHEMBL5959489 | 0.89 | PPARD (0.50) | PPARDPPARGPPARAALDH1A1HPGD | |
| SCHEMBL5959525 | 0.85 | FFAR1 (0.51) | PPARDPPARGPPARALMNAMAPT | |
| SCHEMBL5959551 | 0.85 | PPARD (0.59) | PPARDPPARGPPARAALDH1A1LMNA | |
| SCHEMBL6428168 | 0.85 | PPARD (0.49) | PPARDPPARGPPARALMNASMN1; SMN2 | |
| SCHEMBL5959644 | 0.84 | LMNA (0.54) | PPARDPPARGPPARAALDH1A1HPGD | |
| SCHEMBL5959392 | 0.84 | PPARD (0.54) | PPARDPPARGPPARAALDH1A1HPGD | |
| SCHEMBL5959352 | 0.83 | PPARD (0.48) | PPARDPPARGPPARAALDH1A1HPGD | |
| SCHEMBL5959510 | 0.83 | PPARD (0.48) | PPARDPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091245-B2 | Compounds, their preparation and use | NOVO NOVDISK A/S (DK) | 2006-08-15 | — | — | US | claimed |
| US-20040143006-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-22 | — | — | US | claimed |
| US-7091245-B2 | Compounds, their preparation and use | NOVO NOVDISK A/S (DK) | 2006-08-15 | — | — | US | disclosed |
| EP-1537076-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-20040143006-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-22 | — | — | US | disclosed |
| WO-2004022533-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143006-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.